About Us
Early detection saves lives
Imagion Biosystems exists to help detect cancer earlier and with greater precision, so patients have the best chance at effective treatment.
Our Mission
At Imagion Biosystems, we are working to change how cancer is found and treated.
Too often, cancer is detected late, after it has already spread, or patients undergo unnecessary procedures due to uncertainty in imaging results.
Our mission is to provide imaging tools that bring clarity where today’s methods fall short. We focus on enabling clinicians to detect cancer earlier, with greater confidence, so patients have more options and better outcomes.
Our Technology
We are advancing MagSense® molecular MRI (mMRI), a new approach that combines the power of MRI with molecular-level targeting.
MagSense® uses bio-safe magnetic nanoparticles (superparamagnetic iron-oxide nanoparticles, SPIONS) linked to molecules that attach to specific cancer biomarkers.
By combining the high resolution of MRI with the specificity of our imaging agents, we have the potential to detect tumors, with certainty, that are up to 10 times smaller than what current standard imaging can detect, helping clinicians see cancer sooner and more precisely, without exposing patients to radiation.
aNANOtation
WHAT ARE SPIONS?
Our Journey
Founded with a vision to revolutionize cancer detection, Imagion Biosystems has grown from early-stage innovation to active clinical development.
Key milestones include:
- Completion of a multi-site Phase I clinical study of our MagSense® HER2 imaging agent in breast cancer
- IND preparation for Phase II clinical trials to evaluate diagnostic performance in detecting nodal metastases in HER2-positive breast cancer
- Development of additional MagSense® imaging agents for prostate and ovarian cancer detection
- Ongoing partnerships with leading institutions and clinical sites
MagSense® HER2 Imaging Agent Clinical Study
Imagion Biosystems is preparing for a Phase II clinical trial of our MagSense® HER2 imaging agent, focused on breast cancer detection.
Our trials are designed to demonstrate the potential of molecular MRI to improve diagnostic confidence, guide biopsies, and reduce unnecessary procedures.
Meet our team of Imagioneers
Geoff Hollis
Marie Zhang, PhD
Elana Levin
Carmen Solkowski
Mee Wa Wong, PhD
Sormeh Mahjouri
Koushik Govindarajan
Nitika Neha
Eric Smith-Nguyen
Hannah Campbell
Casie Ost
Michael Shun
Kevin Forero
Recent Milestones
Looking to make a difference? Let’s get connected!
We respect your inbox. You’ll only hear from us when we have meaningful updates to share.